460 related articles for article (PubMed ID: 16096014)
1. Cancer-specific gene therapy.
Lo HW; Day CP; Hung MC
Adv Genet; 2005; 54():235-55. PubMed ID: 16096014
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antitumor activity by probasin promoter-directed p202 expression.
Wen Y; Giri D; Yan DH; Spohn B; Zinner RG; Xia W; Thompson TC; Matusik RJ; Hung MC
Mol Carcinog; 2003 Jul; 37(3):130-7. PubMed ID: 12884364
[TBL] [Abstract][Full Text] [Related]
3. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
5. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
6. p202, an interferon-inducible negative regulator of cell growth, is a target of the adenovirus E1A protein.
Xin H; D'Souza S; Fang L; Lengyel P; Choubey D
Oncogene; 2001 Oct; 20(47):6828-39. PubMed ID: 11687962
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
8. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Kong BH; Song Y; Ma DX; Qu X; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
[TBL] [Abstract][Full Text] [Related]
9. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity.
Gu J; Andreeff M; Roth JA; Fang B
Gene Ther; 2002 Jan; 9(1):30-7. PubMed ID: 11850720
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line.
Zhang L; Gu J; Lin T; Huang X; Roth JA; Fang B
Gene Ther; 2002 Sep; 9(18):1262-70. PubMed ID: 12215894
[TBL] [Abstract][Full Text] [Related]
11. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.
Tai YT; Strobel T; Kufe D; Cannistra SA
Cancer Res; 1999 May; 59(9):2121-6. PubMed ID: 10232598
[TBL] [Abstract][Full Text] [Related]
12. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo.
Gu J; Zhang L; Huang X; Lin T; Yin M; Xu K; Ji L; Roth JA; Fang B
Oncogene; 2002 Jul; 21(31):4757-64. PubMed ID: 12101414
[TBL] [Abstract][Full Text] [Related]
13. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
15. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
Van Houdt WJ; Haviv YS; Lu B; Wang M; Rivera AA; Ulasov IV; Lamfers ML; Rein D; Lesniak MS; Siegal GP; Dirven CM; Curiel DT; Zhu ZB
J Neurosurg; 2006 Apr; 104(4):583-92. PubMed ID: 16619663
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.
Yang L; Cao Z; Li F; Post DE; Van Meir EG; Zhong H; Wood WC
Gene Ther; 2004 Aug; 11(15):1215-23. PubMed ID: 15141159
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.
Ito H; Kanzawa T; Miyoshi T; Hirohata S; Kyo S; Iwamaru A; Aoki H; Kondo Y; Kondo S
Hum Gene Ther; 2005 Jun; 16(6):685-98. PubMed ID: 15960600
[TBL] [Abstract][Full Text] [Related]
18. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
[TBL] [Abstract][Full Text] [Related]
19. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
Bilsland AE; Anderson CJ; Fletcher-Monaghan AJ; McGregor F; Evans TR; Ganly I; Knox RJ; Plumb JA; Keith WN
Oncogene; 2003 Jan; 22(3):370-80. PubMed ID: 12545158
[TBL] [Abstract][Full Text] [Related]
20. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
